Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Rhea-AI Summary

DBV Technologies (DBVT) has released its Half-Year report on the liquidity contract with ODDO BHF. As of December 31, 2024, the liquidity account held 266,868 DBV Technologies shares and €106,930.51 in cash. This represents a significant change from the contract's implementation on July 1, 2018, which started with 41,159 shares and €432,367.25.

During the period from July 1, 2024, to December 31, 2024, trading activity included 1,682 buy transactions and 1,800 sales transactions. The total volume traded comprised 404,081 shares (€296,390.97) in purchases and 440,957 shares (€340,906.76) in sales.

Positive

• Net positive cash flow from trading activities of €44,515.79
• Higher sales volume (440,957 shares) compared to purchase volume (404,081 shares) indicating market liquidity

Negative

• Significant decrease in cash position from €432,367.25 to €106,930.51 since contract inception

AMF Regulated Information
Châtillon, France, January 13, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024:

• 266,868 DBV Technologies shares,
• € 106,930.51.

When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:

• 41,159 DBV Technologies shares,
• € 432,367.25.

Over the period from July 1, 2024, to December 31, 2024, the following transactions were executed:

• 1682 buy transactions,
• 1800 sales transactions.

Over this same period, the volumes traded represented:

• 404,081 shares and € 296,390.97 on purchases,
• 440,957 shares and € 340,906.76 on sales.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary Viaskin® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

What is the current balance of DBV Technologies' (DBVT) liquidity account as of December 31, 2024?

As of December 31, 2024, the liquidity account held 266,868 DBV Technologies shares and €106,930.51 in cash.

How many shares were traded in DBVT's liquidity contract during H2 2024?

During H2 2024, there were 404,081 shares purchased and 440,957 shares sold, totaling 845,038 shares traded.

What was the trading value of DBVT shares in the liquidity contract for H2 2024?

The trading value was €296,390.97 for purchases and €340,906.76 for sales, totaling €637,297.73.

How has DBVT's liquidity account changed since its implementation in July 2018?

Since July 2018, the account's share balance increased from 41,159 to 266,868 shares, while cash decreased from €432,367.25 to €106,930.51.